Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Fuchs Endothelial Dystrophy

In brief

The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.

Key facts

Study ID

NCT04051463

Run by

Price Vision Group

People needed

29

Starts

2019-08-05

Expected to finish

2020-07-01

Last updated by the study team

2021-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age
• Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.
• Patient is able and willing to administer eye drops.
• Patient is able to comprehend and has signed the Informed Consent form.

You may not qualify if…

• Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.
• Known sensitivity to any of the ingredients in the study medications.
• Abnormal eyelid function.
• History of herpetic keratitis.
• History of non-compliance with using prescribed medication.
• Current or planned pregnancy within the study duration.
• Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.
• Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.

Where it is running

• Price Vision Group — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.